Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE:301520)

SHE:301520 Revenue

Anhui Wanbang Pharmaceutical Technology had revenue of 96.47M CNY in the quarter ending September 30, 2026, with 54.14% growth. This brings the company's total for the last twelve months to 248.98M, down -15.66% year-over-year. In the year 2025, Anhui Wanbang Pharmaceutical Technology had annual revenue of 274.18M, down -27.67%. That makes Anhui Wanbang Pharmaceutical Technology the 29,963rd largest company in the world by revenue and 4,943rd in China.

• Revenue (ttm): 248.98M
• Revenue Growth: -15.66%
• P/S Ratio: 21.63
• Revenue / Employee: 462.80K
• Employees: 538
• Market Cap: 5.39B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Clinical Research Services 217.94M 79.5%
• Other 34.43M 12.6%
• Pharmaceutical Research Services 21.81M 8.0%

Fiscal year ended Dec 31, 2025 See the full SHE:301520 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	274.18M	-104.91M	-27.67%
Dec 31, 2024	379.09M	37.28M	10.91%
Dec 31, 2023	341.81M	81.03M	31.07%
Jan 1, 2023	260.78M	49.69M	23.54%
Dec 31, 2021	211.09M	71.96M	51.72%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error